XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Note 13 - Segment Information
 6 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 13. Segment Information

 

As of September 30, 2020, we had four reportable segments, Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring. Results for the Cold Chain Packaging division, which we exited during the year ended March 31, 2020, are now presented within Corporate and Other. The following tables set forth our segment information: 

 

  

Three Months Ended September 30, 2020

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $11,552  $7,558  $9,131  $3,619  $-  $31,860 

Gross profit

 $8,770  $4,852  $6,212  $1,368  $83  $21,285 

Reconciling items (2)

                      (18,901)

Earnings before income taxes

                     $2,384 

 

  

Three Months Ended September 30, 2019

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $12,094  $8,960  $-  $3,586  $896  $25,536 

Gross profit

 $8,723  $5,557  $-  $1,221  $85  $15,586 

Reconciling items (2)

                      (11,812)

Earnings before income taxes

                     $3,774 

 

  

Six Months Ended September 30, 2020

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $24,619  $15,238  $15,080  $6,864  $-  $61,801 

Gross profit

 $18,790  $9,541  $10,678  $2,552  $64  $41,625 

Reconciling items (2)

                      (38,487)

Earnings before income taxes

                     $3,138 

 

  

Six Months Ended September 30, 2019

 
  

Sterilization and Disinfection Control

  

Instruments

  

Biopharmaceutical Development

  

Continuous Monitoring

  

Corporate and Other

  

Total

 

Revenues (1)

 $24,204  $18,504  $-  $6,903  $2,213  $51,824 
Gross profit $17,233  $11,639  $-  $2,506  $412  $31,790 

Reconciling items (2)

                      (22,591)

Earnings before income taxes

                     $9,199 

 

 

(1)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(2)

Reconciling items include selling, general and administrative, research and development, interest expense and amortization of debt discount, and other (income) expenses.

 

The following table sets forth assets by reportable segment: 

 

  

September 30, 2020

  

March 31, 2020

 

Sterilization and Disinfection Control

 $68,571  $73,103 

Instruments

  29,735   31,025 

Biopharmaceutical Development

  194,570   182,758 

Continuous Monitoring

  28,625   29,732 

Corporate and administrative

  267,431   103,588 

Total

 $588,932  $420,206